cyclobutanecarboxylic acid {3-[2-(imidazo[1,2-a]pyridin-6-ylamino)-pyrrolo[2,3-d]pyrimidin-7-yl]-propyl}-amide | 1243268-51-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: cyclobutanecarboxylic acid {3-[2-(imidazo[1,2-a]pyridin-6-ylamino)-pyrrolo[2,3-d]pyrimidin-7-yl]-propyl}-amide
• 英文别名: N-[3-[2-(imidazo[1,2-a]pyridin-6-ylamino)pyrrolo[2,3-d]pyrimidin-7-yl]propyl]cyclobutanecarboxamide
• CAS: 1243268-51-0
• 化学式: C₂₁H₂₃N₇O
• 分子量: 389.46
• InChiKey: MJOYLEXXZJPKQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  89.1
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• PYRROLOPYRIMIDINES AND USED AS KINASE INHIBITORS
  申请人：Mciver Edward Giles

  公开号：US20120088753A1

  公开（公告）日：2012-04-12

  The invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: R 1 is —NR 7 (CO)R 11 ; R 2 is aryl, heteroaryl, fused aryl-C 3-6- heterocycloalkyl or fused heteroaryl-C 3-6- heterocycloalkyl, each of which is optionally substituted; each R 7 is selected from hydrogen, C 1-6- alkyl and C 3-7- cycloalkyl, wherein said C1-6-alkyl is optionally substituted by one or more halogens; each R 11 is independently selected from C 1-6 -alkyl, C 3-7- cycloalkyl, C 1-6 alkyl-C 3-7- cycloalkyl, Ĉ-heterocycloalkyl, aryl and heteroaryl, each of which may be optionally substituted. Further aspects of the invention relate to pharmaceutical compositions comprising the same, and methods for treating or preventing a disorder selected from cancer, septic shock, Primary open Angle Glaucoma (POAG), hyperplasia, rheumatoid arthritis, psoriasis, artherosclerosis, retinopathy, osteoarthritis, endometriosis, chronic inflammation and Alzheimer's disease. Another aspect of the invention relates to the use of a compound as described above in the preparation of a medicament for the prevention or treatment of a disorder caused by, associated with or accompanied by any abnormal kinase activity, wherein the kinase is selected from TBK1, ERK8, CDK2, MARK3, YES1, VEG-FR, IKKepsilon and combinations thereof.

  本发明涉及一种式（I）的化合物，或其药学上可接受的盐或酯，其中：R1为—NR7（CO）R11；R2为芳基，杂环芳基，融合芳基-C3-6-杂环烷基或融合杂环芳基-C3-6-杂环烷基，每个基团均可选择性地被取代；每个R7为氢、C1-6-烷基和C3-7-环烷基，其中所述的C1-6-烷基可被一个或多个卤素取代；每个R11是独立选择的C1-6-烷基，C3-7-环烷基，C1-6-烷基-C3-7-环烷基，Ĉ-杂环烷基，芳基和杂环芳基，每个基团均可选择性地被取代。本发明的另一方面涉及包含上述化合物的制药组合物，以及治疗或预防癌症、败血症、原发性开角青光眼（POAG）、增生、类风湿性关节炎、银屑病、动脉粥样硬化、视网膜病变、骨关节炎、子宫内膜异位症、慢性炎症和阿尔茨海默病等疾病的方法。本发明的另一方面涉及使用上述化合物制备药物，用于预防或治疗由任何异常激酶活性引起、与之相关或伴随的疾病，其中激酶选择自TBK1、ERK8、CDK2、MARK3、YES1、VEG-FR、IKKepsilon及其组合。
• PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS
  申请人：Medical Research Council Technology

  公开号：EP2403853A1

  公开（公告）日：2012-01-11